Corrigendum: Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors (Annals of Oncology (2012) 23 (463–471) (DOI: 10.1093/annonc/mdr137)

  1. Soria, J.-C.
  2. Cortes, J.
  3. Massard, C.
  4. Armand, J.-P.
  5. De Andreis, D.
  6. Ropert, S.
  7. Lopez, E.
  8. Catteau, A.
  9. James, J.
  10. Marier, J.-F.
  11. Beliveau, M.
  12. Martell, R.E.
  13. Baselga, J.
Aldizkaria:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Argitalpen urtea: 2019

Alea: 30

Zenbakia: 6

Orrialdeak: 1020

Mota: Hutsen zuzenketa

DOI: 10.1093/ANNONC/MDY532 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus